

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lutz Robert Matthew</u> <hr/> (Last) (First) (Middle) 900 NORTHBROOK DRIVE SUITE 200 <hr/> (Street) TREVOSE PA 19053 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/03/2019	3. Issuer Name and Ticker or Trading Symbol <u>Strongbridge Biopharma plc [SBBP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Financial Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	40,811 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (Right to Buy)	10/06/2015	10/06/2019	Common Stock	31,818	8.06	D
Stock Option (Right to Buy)	10/06/2016	10/06/2019	Common Stock	31,818	10.74	D
Stock Option (Right to Buy)	10/06/2017	10/06/2019	Common Stock	36,363	13.43	D
Stock Option (Right to Buy)	(2)	06/25/2025	Common Stock	7,575	14.37	D
Stock Option (Right to Buy)	(3)	06/25/2025	Common Stock	7,575	14.37	D
Stock Option (Right to Buy)	(4)	06/25/2025	Common Stock	7,577	14.37	D
Stock Option (Right to Buy)	(5)	02/26/2026	Common Stock	63,000	3.94	D
Stock Option (Right to Buy)	(6)	02/23/2027	Common Stock	175,000	2.9	D
Stock Option (Right to Buy)	(7)	02/05/2028	Common Stock	114,000	6.65	D
Stock Option (Right to Buy)	(8)	02/20/2029	Common Stock	110,000	4.67	D

Explanation of Responses:

- Of the 40,811 shares, 24,500 ordinary shares are held in the form of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date.
- This option vested in 16 equal, quarterly installments beginning August 26, 2015, and is fully exercisable.
- This option vested in 16 equal, quarterly installments beginning October 16, 2015, and is fully exercisable.
- This option becomes 100% exercisable upon a change of control of the Issuer, provided the Reporting Person is employed by the Issuer on such date.
- This option vests in sixteen equal quarterly installments beginning May 26, 2016, provided the Reporting Person is employed by the Issuer on each vesting date.
- This option vests in sixteen equal quarterly installments beginning May 23, 2017, provided the Reporting Person is employed by the Issuer on each vesting date.
- This option vests in sixteen equal quarterly installments beginning May 5, 2018, provided the Reporting Person is employed by the Issuer on each vesting date.
- This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Stephen J. Long, as attorney-in-fact

09/03/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints each of Stephen J. Long and Judith Goldberg as such person's true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution and full power to act alone and without the other, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

(a) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID (or any successor form), including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) or any rule or regulation of the SEC promulgated thereunder;

(b) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Strongbridge Biopharma plc (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (or any successor forms);

(c) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(d) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact, except that in respect of any person herein appointed as an attorney-in-fact of the undersigned, this Power of Attorney shall be revoked and shall cease to be effective immediately with respect to such person at such time as such person shall no longer be employed by any of the Company and its subsidiaries.

IN WITNESS WHEREOF, the undersigned has executed this instrument as of the 28th day of August, 2019.

By:/s/ Robert Matthew Lutz

Name: Robert Matthew Lutz